20 April 2017

10 Spring Gardens, London

Draft Agenda

The meeting will start promptly at 10am and is expected to finish at approximately 6pm.

Please note that this agenda is subject to change prior to the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Code of conduct for members of the public attending the meeting – Part 1 only (open session)
  3. Apologies – Part 1 only (open session)
  4. Any other business – Part 1 only (open session)
  5. Minutes from the last Committee meeting held on 23 March 2017 – Part 1 only (open session)
  6. Appraisal of lesinurad for treating chronic hyperuricaemia in people with gout [ID761]
    • 6.1. Declarations of interest – Part 1 only (open session)
    • 6.2. Introduction by the Chair, Dr Amanda Adler – Part 1 only (open session)
    • 6.3. Presentation by the Chair, Dr Amanda Adler – Part 1 AND part 2 (open and closed session)
    • 6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of daratumumab monotherapy for treating relapsed and refractory multiple myeloma [ID933]
    • 7.1. Declarations of interest – Part 1 only (open session)
    • 7.2. Introduction by the Chair, Dr Amanda Adler – Part 1 only (open session)
    • 7.3. Presentation by the Chair, Dr Amanda Adler – Part 1 AND part 2 (open and closed session)
    • 7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  8. Appraisal of adalimumab, etanercept and ustekinumab for treating severe, chronic plaque psoriasis in children and young people [ID854]
    • 8.1. Declarations of interest – Part 1 only (open session)
    • 8.2. Introduction by the Chair, Dr Amanda Adler – Part 1 only (open session)
    • 8.3. Presentation by the Chair, Dr Amanda Adler – Part 1 AND part 2 (open and closed session)
    • 8.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  9. Appraisal of pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282) [ID837]
    • 9.1. Declarations of interest – Part 1 only (open session)
    • 9.2. Introduction by the Chair, Dr Amanda Adler – Part 1 only (open session)
    • 9.3. Presentation by the Chair, Dr Amanda Adler – Part 1 AND part 2 (open and closed session)
    • 9.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on 23 May 2017, at Prospero House, 241 Borough High Street, London, SE1 1GA.

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on 4 April 2017Please note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Josh South.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.